LNZ100 is a single-use, once-daily eye drop containing aceclidine, a small molecule acetylcholine receptor agonist that causes miosis.

In Teva Branded Pharm. Prods. R&D v. Amneal Pharms. of N.Y., LLC, the US District Court for the District of New Jersey ordered Teva to delist ...

The new drug application resubmission of rivoceranib/camrelizumab in the first line in unresectable or metastatic ...

Pharmacists insist no policies have changed as doctors try to determine why their patients have to chase down medication ...

At the Neurocritical Care Society's (NCS) 22nd Annual Meeting this week, a University of Cincinnati researcher presented ...

LENZ Therapeutics said the submission for the treatment of presbyopia is supported by the positive data results from a Phase 3 study. Aceclidine is a new chemical entity in the U.S. and isn't approved ...

Learn how to effectively navigate the challenges of CMC in breakthrough drug development. Discover key strategies here.

CStone Pharmaceuticals (HK:2616) has released an update. CStone Pharmaceuticals has announced the publication of a patent for ...

The FDA was expected to decide on the application of sotorasib and panitumumab for the treatment of metastatic colorectal ...

The regulator has delayed its respective decision dates on whether to grant full approval to Amgen’s Lumakras in metastatic ...

Innovative application of an existing drug offers promising alternative treatment to traditional chemotherapy for patients with appendix cancer.

Lo, PhD, has been appointed the new Editor-in-Chief of the journal ASSAY and Drug Development Technologies. Dr. Lo is ...